Transition Plans for Covid-19 Products are Amongst CDRH FY2023 Priorities
FDA Law Blog
OCTOBER 18, 2022
By Véronique Li, Senior Medical Device Regulation Expert & Philip Won — Last week, our blog post advised planning a transition strategy in advance of the news of the termination of the Covid-19 public health emergency. The 2013 guidance documents include, but are not limited to, in vitro diagnostic and clinical trial considerations.
Let's personalize your content